Table 1.
Baseline characteristics
| Aerobic capacity+ (n=48) | Aerobic capacity- (n=28) | P value | |
| Age, years | 34 (22–48) | 38 (25–51) | 0.09 |
| Male | 12 (43%) | 22 (46%) | 0.4 |
| Body mass index, kg/m2 | 27±5 | 29±6 | 0.1 |
| Prior tricuspid valve repair | 6 (21%) | 13 (27%) | 0.6 |
| NYHA II–IV | 21 (75%) | 43 (90%) | 0.09 |
| Comorbidities | |||
| Hypertension | 5 (18%) | 9 (19%) | 0.7 |
| Diabetes | 1 (4%) | 2 (4%) | 0.8 |
| Coronary artery disease | – | 2 (4%) | – |
| Atrial flutter/tachycardia | 6 (21%) | 12 (25%) | 0.4 |
| Atrial fibrillation | 4 (14%) | 9 (18%) | 0.6 |
| Supraventricular tachycardia | 3 (11%) | 6 (13%) | 0.8 |
| Non-sustained ventricular tachycardia | 1 (4%) | 1 (2%) | 0.7 |
| Laboratory data | |||
| NT proBNP, pg/mL | 137 (91–322) | 152 (73–412) | 0.4 |
| Haemoglobin, g/dL | 13.8±1.4 | 14.1±2.1 | 0.3 |
| Estimated GFR, mL/min/1.73 m2 | 85±20 | 87±16 | 0.4 |
| Medications | |||
| Loop diuretics | 11 (39%) | 21 (44%) | 0.3 |
| Beta blockers | 8 (29%) | 11 (23%) | 0.5 |
| ACEI/ARB | 5 (18%) | 10 (21%) | 0.7 |
| Aldosterone antagonist | – | 1 (2%) | – |
ACEI, ACE inhibitor; ARB, angiotensin II receptor blockers; GFR, glomerular filtration rate; NT proBNP, N-terminal pro-brain natriuretic peptide; VO2, oxygen consumption.